Local  	Local  	 JJ	B-NP
tolerability  	tolerability  	 NN	I-NP
and  	and  	 CC	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
Ketospray速  	Ketospray速  	 CD	B-NP
10 	10 	 CD	O
%  	%  	 NN	O
cutaneous  	cutaneous  	 FW	B-NP
spray  	spray  	 FW	I-NP
solution  	solution  	 FW	I-NP
Orally  	Orally  	 FW	O
administrated  	administrated  	 FW	O
nonsteroidal  	nonsteroidal  	 FW	B-NP
anti-inflammatory  	anti-inflammatory  	 JJ	I-NP
drugs  	drugs  	 NNS	I-NP
are  	are  	 VBP	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
variety  	variety  	 NN	O
of  	of  	 IN	O
acute  	acute  	 JJ	O
and  	and  	 CC	O
chronic  	chronic  	 JJ	B-NP
pain  	pain  	 NN	I-NP
conditions  	conditions  	 NNS	I-NP
but  	but  	 CC	O
their  	their  	 PRP$	O
use  	use  	 NN	O
may  	may  	 MD	O
be  	be  	 VB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
serious  	serious  	 JJ	B-NP
systemic  	systemic  	 JJ	I-NP
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
which  	which  	 WDT	O
are  	are  	 VBP	O
correlated  	correlated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
therapeutic  	therapeutic  	 JJ	B-NP
plasma  	plasma  	 NN	I-NP
levels  	levels  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
drug 	drug 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
minimize  	minimize  	 VB	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
drug  	drug  	 NN	O
related  	related  	 VBN	O
systemic  	systemic  	 JJ	B-NP
events 	events 	 NNS	I-NP
,  	,  	 ,	O
topical  	topical  	 JJ	B-NP
formulations  	formulations  	 NNS	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
nonsteroidal  	nonsteroidal  	 JJ	I-NP
anti-inflammatory  	anti-inflammatory  	 JJ	I-NP
drugs  	drugs  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
developed 	developed 	 VBN	O
.  	.  	 .	O
A  	A  	 DT	O
recently  	recently  	 RB	O
performed  	performed  	 VBN	B-NP
review  	review  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	O
from  	from  	 IN	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
double-blind 	double-blind 	 NNP	B-NP
,  	,  	 ,	O
placebo  	placebo  	 VBD	O
controlled  	controlled  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
with  	with  	 IN	O
topically  	topically  	 NN	O
applied  	applied  	 VBD	O
NSAIDs  	NSAIDs  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
acute  	acute  	 JJ	O
pain  	pain  	 NN	O
confirmed  	confirmed  	 VBD	O
the  	the  	 DT	O
previously  	previously  	 RB	O
described  	described  	 VBN	O
pain  	pain  	 NN	B-NP
relief  	relief  	 NN	I-NP
effectiveness 	effectiveness 	 NN	I-NP
.  	.  	 .	O
For  	For  	 IN	O
all  	all  	 DT	O
topical  	topical  	 JJ	B-NP
nonsteroidal  	nonsteroidal  	 JJ	I-NP
anti-inflammatory  	anti-inflammatory  	 JJ	I-NP
drugs  	drugs  	 NNS	I-NP
combined 	combined 	 VBN	O
,  	,  	 ,	O
in  	in  	 IN	O
comparison  	comparison  	 NN	O
to  	to  	 TO	O
placebo 	placebo 	 VB	O
,  	,  	 ,	O
the  	the  	 DT	O
number  	number  	 NN	B-NP
needed  	needed  	 VBN	I-NP
to  	to  	 TO	I-NP
treat  	treat  	 VB	I-NP
( 	( 	 -LRB-	O
NNT 	NNT 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
achieve  	achieve  	 VB	O
a  	a  	 DT	O
clinically  	clinically  	 JJ	O
meaningful  	meaningful  	 JJ	O
pain  	pain  	 NN	B-NP
relief  	relief  	 NN	I-NP
of  	of  	 IN	O
50  	50  	 CD	O
%  	%  	 NN	O
was  	was  	 VBD	O
4.5  	4.5  	 CD	O
( 	( 	 -LRB-	O
3.9  	3.9  	 CD	O
to  	to  	 TO	O
5.3 	5.3 	 CD	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
treatment  	treatment  	 NN	B-NP
periods  	periods  	 NNS	I-NP
of  	of  	 IN	O
6  	6  	 CD	O
to  	to  	 TO	O
14  	14  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
Local  	Local  	 JJ	O
skin  	skin  	 NN	O
reactions  	reactions  	 NNS	O
were  	were  	 VBD	O
generally  	generally  	 RB	O
mild  	mild  	 JJ	O
and  	and  	 CC	O
transient 	transient 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
did  	did  	 VBD	O
not  	not  	 RB	O
differ  	differ  	 VB	O
from  	from  	 IN	O
placebo 	placebo 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
present  	present  	 NN	O
is  	is  	 VBZ	O
an  	an  	 DT	O
observational 	observational 	 NN	B-NP
,  	,  	 ,	O
multicenter 	multicenter 	 NN	B-NP
,  	,  	 ,	O
open-label 	open-label 	 NNP	B-NP
,  	,  	 ,	O
non-interventional 	non-interventional 	 NNP	B-NP
,  	,  	 ,	O
post-authorization  	post-authorization  	 JJ	B-NP
safety  	safety  	 NN	I-NP
study  	study  	 NN	I-NP
as  	as  	 IN	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
defined  	defined  	 VBN	O
by  	by  	 IN	O
Article  	Article  	 NNP	O
21  	21  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
European  	European  	 NNP	O
Clinical  	Clinical  	 NNP	B-NP
Trials  	Trials  	 NNP	I-NP
Directive  	Directive  	 NNP	I-NP
2001 	2001 	 CD	O
/ 	/ 	 CD	O
20 	20 	 CD	O
/ 	/ 	 CD	O
EC 	EC 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
main  	main  	 JJ	O
objective  	objective  	 NN	B-NP
of  	of  	 IN	O
this  	this  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
local  	local  	 JJ	O
tolerability  	tolerability  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
of  	of  	 IN	O
static  	static  	 JJ	O
and  	and  	 CC	O
pain  	pain  	 NN	O
on  	on  	 IN	O
movement  	movement  	 NN	B-NP
intensity  	intensity  	 NN	I-NP
reduction  	reduction  	 NN	I-NP
of  	of  	 IN	I-NP
Ketospray速  	Ketospray速  	 CD	I-NP
10 	10 	 CD	O
%  	%  	 NN	O
cutaneous  	cutaneous  	 NN	B-NP
spray  	spray  	 NN	I-NP
solution  	solution  	 NN	I-NP
administered  	administered  	 VBN	O
in  	in  	 IN	O
accordance  	accordance  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
marketing  	marketing  	 NN	B-NP
authorization  	authorization  	 NN	I-NP
and  	and  	 CC	O
last  	last  	 JJ	O
version  	version  	 NN	O
of  	of  	 IN	O
summary  	summary  	 NN	O
of  	of  	 IN	O
product  	product  	 NN	B-NP
characteristics  	characteristics  	 NNS	I-NP
approved  	approved  	 VBN	O
by  	by  	 IN	O
National  	National  	 NNP	B-NP
Medicines  	Medicines  	 NNP	I-NP
Agency  	Agency  	 NNP	O
of  	of  	 IN	O
Romania 	Romania 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
compliance  	compliance  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
Post-marketing  	Post-marketing  	 JJ	B-NP
study  	study  	 NN	I-NP
type 	type 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
assignment  	assignment  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
patient  	patient  	 NN	O
to  	to  	 TO	O
a  	a  	 DT	O
particular  	particular  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
strategy  	strategy  	 NN	I-NP
fell  	fell  	 VBD	O
within  	within  	 IN	O
current  	current  	 JJ	O
practice 	practice 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
prescription  	prescription  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
medicine  	medicine  	 NN	O
was  	was  	 VBD	O
not  	not  	 RB	O
subject  	subject  	 JJ	O
to  	to  	 TO	O
compliance  	compliance  	 NN	O
with  	with  	 IN	O
predefined  	predefined  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
'  	'  	 POS	O
characteristics 	characteristics 	 NNS	O
.  	.  	 .	O
No  	No  	 DT	O
specific 	specific 	 JJ	O
,  	,  	 ,	O
out  	out  	 RB	O
of  	of  	 IN	O
the  	the  	 DT	O
daily  	daily  	 JJ	O
practice  	practice  	 NN	O
routine  	routine  	 JJ	B-NP
diagnostic 	diagnostic 	 NN	I-NP
,  	,  	 ,	O
monitoring 	monitoring 	 NN	O
,  	,  	 ,	O
instrumental  	instrumental  	 JJ	O
or  	or  	 CC	O
laboratory  	laboratory  	 NN	B-NP
assessments  	assessments  	 NNS	I-NP
were  	were  	 VBD	O
foreseen  	foreseen  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	B-NP
protocol 	protocol 	 NN	I-NP
.  	.  	 .	O
Patients 	Patients 	 NNS	O
'  	'  	 POS	O
data  	data  	 NNS	O
were  	were  	 VBD	O
collected  	collected  	 VBN	O
into  	into  	 IN	O
respective  	respective  	 JJ	O
case  	case  	 NN	B-NP
report  	report  	 NN	I-NP
forms 	forms 	 NNS	I-NP
.  	.  	 .	O
Study  	Study  	 NN	B-NP
medication 	medication 	 NN	I-NP
,  	,  	 ,	O
Ketoprofen  	Ketoprofen  	 NNP	B-NP
10 	10 	 CD	O
%  	%  	 NN	O
Cutaneous  	Cutaneous  	 NNP	B-NP
Spray  	Spray  	 NNP	I-NP
Solution  	Solution  	 NNP	I-NP
was  	was  	 VBD	O
administered  	administered  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
affected  	affected  	 JJ	O
area  	area  	 NN	O
at  	at  	 IN	O
the  	the  	 DT	O
dose  	dose  	 NN	O
of  	of  	 IN	O
3-6  	3-6  	 CD	O
spray  	spray  	 NN	O
puffs 	puffs 	 NN	O
,  	,  	 ,	O
2-3  	2-3  	 CD	O
times  	times  	 NNS	O
a  	a  	 DT	O
day 	day 	 NN	O
,  	,  	 ,	O
for  	for  	 IN	O
7  	7  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
According  	According  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
study  	study  	 NN	B-NP
type 	type 	 NN	I-NP
,  	,  	 ,	O
descriptive  	descriptive  	 JJ	B-NP
statistical  	statistical  	 JJ	I-NP
methods  	methods  	 NNS	I-NP
were  	were  	 VBD	O
applied 	applied 	 VBN	O
.  	.  	 .	O
Since  	Since  	 IN	O
almost  	almost  	 RB	O
half  	half  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
combination  	combination  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
pain  	pain  	 NN	B-NP
relieving  	relieving  	 NN	I-NP
medications 	medications 	 NN	I-NP
,  	,  	 ,	O
sizing  	sizing  	 VBG	O
of  	of  	 IN	O
the  	the  	 DT	O
pain  	pain  	 NN	B-NP
relieving  	relieving  	 NN	I-NP
effects 	effects 	 NNS	I-NP
,  	,  	 ,	O
as  	as  	 IN	O
NNT 	NNT 	 NNP	B-NP
,  	,  	 ,	O
between  	between  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
groups  	groups  	 NNS	O
was  	was  	 VBD	O
made 	made 	 VBN	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
2020  	2020  	 CD	O
study  	study  	 NN	B-NP
subjects  	subjects  	 NNS	I-NP
in  	in  	 IN	O
safety  	safety  	 NN	O
and  	and  	 CC	O
ITT  	ITT  	 NNP	B-NP
analysis  	analysis  	 NN	I-NP
population  	population  	 NN	I-NP
and  	and  	 CC	O
1802  	1802  	 CD	O
( 	( 	 -LRB-	O
89 	89 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
PP  	PP  	 NNP	B-NP
efficacy  	efficacy  	 JJ	I-NP
analysis  	analysis  	 NN	I-NP
population 	population 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
4  	4  	 CD	O
types  	types  	 NNS	O
of  	of  	 IN	O
injuries 	injuries 	 NNS	O
:  	:  	 :	O
non-complicated  	non-complicated  	 NNP	B-NP
strain-sprain  	strain-sprain  	 NNP	I-NP
( 	( 	 -LRB-	O
555 	555 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
soft  	soft  	 JJ	O
tissue  	tissue  	 NN	O
contusion  	contusion  	 NNS	O
( 	( 	 -LRB-	O
323 	323 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
low  	low  	 JJ	O
back  	back  	 JJ	O
pain  	pain  	 NN	O
( 	( 	 -LRB-	O
461 	461 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
osteoarthritis  	osteoarthritis  	 NNS	B-NP
( 	( 	 -LRB-	O
681  	681  	 CD	O
patients 	patients 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Ten  	Ten  	 CD	O
patients  	patients  	 NNS	O
reported  	reported  	 VBD	O
13  	13  	 CD	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
of  	of  	 IN	O
which  	which  	 WDT	O
10  	10  	 CD	O
were  	were  	 VBD	O
recognized  	recognized  	 VBN	O
by  	by  	 IN	O
investigators  	investigators  	 NNS	B-NP
as  	as  	 IN	O
adverse  	adverse  	 JJ	O
drug  	drug  	 NN	B-NP
reactions 	reactions 	 NNS	I-NP
.  	.  	 .	O
All  	All  	 DT	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
were  	were  	 VBD	O
non-serious 	non-serious 	 JJ	B-NP
,  	,  	 ,	O
listed 	listed 	 VBN	O
,  	,  	 ,	O
application  	application  	 NN	B-NP
site  	site  	 NN	I-NP
skin  	skin  	 NN	I-NP
changes 	changes 	 NNS	I-NP
.  	.  	 .	O
Remarkable  	Remarkable  	 JJ	B-NP
reductions  	reductions  	 NNS	I-NP
of  	of  	 IN	O
static  	static  	 JJ	O
and  	and  	 CC	O
pain  	pain  	 NN	O
on  	on  	 IN	O
movement  	movement  	 NN	B-NP
intensity  	intensity  	 NN	I-NP
were  	were  	 VBD	O
experienced  	experienced  	 VBN	O
by  	by  	 IN	O
patients  	patients  	 NNS	O
irrespective  	irrespective  	 RB	O
of  	of  	 IN	O
the  	the  	 DT	O
type  	type  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
injury  	injury  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
type  	type  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
clinically  	clinically  	 JJ	O
meaningful  	meaningful  	 JJ	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
concomitantly  	concomitantly  	 JJ	B-NP
prescribed  	prescribed  	 JJ	I-NP
pain  	pain  	 NN	I-NP
relieving  	relieving  	 NN	I-NP
medications  	medications  	 NNS	I-NP
was  	was  	 VBD	O
not  	not  	 RB	O
observed  	observed  	 VBN	O
for  	for  	 IN	O
any  	any  	 DT	O
type  	type  	 NN	O
of  	of  	 IN	O
pain 	pain 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
lowest  	lowest  	 JJS	O
NNT  	NNT  	 NNP	B-NP
( 	( 	 -LRB-	O
14 	14 	 CD	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
obtained  	obtained  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
reduction  	reduction  	 NN	O
of  	of  	 IN	O
pain  	pain  	 NN	O
at  	at  	 IN	O
rest  	rest  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
strain-sprain  	strain-sprain  	 JJ	B-NP
or  	or  	 CC	O
soft  	soft  	 JJ	O
tissue  	tissue  	 NN	O
contusions 	contusions 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
highest  	highest  	 JJS	O
NNT  	NNT  	 NNP	B-NP
( 	( 	 -LRB-	O
283 	283 	 LS	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
for  	for  	 IN	O
pain  	pain  	 NN	O
at  	at  	 IN	O
rest  	rest  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
exacerbation  	exacerbation  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
chronic  	chronic  	 JJ	I-NP
pain 	pain 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
post-authorization  	post-authorization  	 JJ	B-NP
study  	study  	 NN	I-NP
confirm  	confirm  	 VBP	O
beneficial  	beneficial  	 JJ	O
pain  	pain  	 NN	B-NP
intensity  	intensity  	 NN	I-NP
reducing  	reducing  	 VBG	I-NP
efficacy  	efficacy  	 NN	I-NP
of  	of  	 IN	O
Ketospray  	Ketospray  	 NNP	B-NP
10 	10 	 CD	O
%  	%  	 NN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
good  	good  	 JJ	O
local  	local  	 JJ	O
tolerability  	tolerability  	 NN	B-NP
of  	of  	 IN	O
7  	7  	 CD	O
days  	days  	 NNS	O
treatment  	treatment  	 NN	B-NP
course 	course 	 NN	I-NP
.  	.  	 .	O
Concomitant  	Concomitant  	 JJ	B-NP
administration  	administration  	 NN	I-NP
of  	of  	 IN	I-NP
systemic  	systemic  	 JJ	I-NP
pain  	pain  	 NN	I-NP
relieving  	relieving  	 NN	I-NP
medication  	medication  	 NN	I-NP
did  	did  	 VBD	O
not  	not  	 RB	O
substantially  	substantially  	 RB	O
contribute  	contribute  	 VB	O
neither  	neither  	 RB	O
to  	to  	 TO	O
the  	the  	 DT	O
relief  	relief  	 NN	O
of  	of  	 IN	O
pain  	pain  	 NN	O
at  	at  	 IN	O
rest  	rest  	 NN	O
nor  	nor  	 CC	O
of  	of  	 IN	O
pain  	pain  	 NN	O
on  	on  	 IN	O
movement  	movement  	 NN	O
among  	among  	 IN	O
the  	the  	 DT	O
subjects  	subjects  	 NNS	B-NP
of  	of  	 IN	O
respective  	respective  	 JJ	O
study  	study  	 NN	B-NP
populations 	populations 	 NNS	I-NP
.  	.  	 .	O
